Company Profile
PepGen Stock Price, News & Catalysts
- Ticker:
- PEPG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.14 USD (+3.46%)
Close
Last updated: August 21, 2026
100M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, PEPG closed up 3.46% at $3.14. No new same-company headline was identified in the current news window.
Company overview
Oligonucleotide Delivery Company
PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle.
PGN-EDODM1
PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression.
FREEDOM2
The FREEDOM2 study is evaluating multiple ascending doses, with early cohorts assessing safety, splice correction, and functional biomarkers.
Future catalysts
- Data from the fully enrolled 10 mg/kg FREEDOM2 cohort are expected in the second half of 2026.
- Data from the 12.5 mg/kg cohort are anticipated in 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PepGen (PEPG)?
PepGen (PEPG) most recently closed at 3.14 USD, a +3.46% move versus the previous session.
What is the market cap of PepGen (PEPG)?
PepGen currently has a market capitalization of 100M USD on BioPharmSignal.
What does PepGen do?
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2 study is evaluating...
On which exchange is PEPG stock listed?
PepGen (PEPG) is associated with NASDAQ, United States, Biopharma.
What is PGN-EDODM1?
PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression.
Which conditions is PepGen targeting with PGN-EDODM1?
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2 study is evaluating...
How does PepGen describe recent progress with PGN-EDODM1?
Data from the fully enrolled 10 mg/kg FREEDOM2 cohort are expected in the second half of 2026. Data from the 12.5 mg/kg cohort are anticipated in 2027.
What is Oligonucleotide?
Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle.